FDA approves Gamifant® as first-ever treatment for adults and children with Macrophage Activation Syndrome in Still's disease

Swedish Orphan Biovitrum AB Sweden

Approval based on the pooled analysis of our pivotal EMERALD and NI-0501-06 studies, showing 54% of patients treated with Gamifant achieved complete response at week 8.View original content:https://www.prnewswire.co.uk/news-releases/fda-approves-gamifant-emapalumab-lzsg-as-first-ever-treatment-for-adults-and-children-with-macrophage-activation-syndrome-in-stills-disease-302493713.html